Danish-Swedish biotech company 2A Pharma has taken the company's HPV vaccine into clinical development in record time. If everything goes well, the vaccine will enter a billion-dollar market in five years. "We have the potential to become quite big," says CEO.
Danish Bavarian Nordic currently has high expenses for several projects, and especially two candidates demands the company's attention. One of them can turn out to be lucrative in several ways.
Danish startup Injurymap receives DKK 2 million (USD 305,175) to market the company's app that gives people with muscle- and joint pain a customized exercise plan to relieve the pain at home.
Swedish biotech firm Cantargia makes a directed share issue of SEK 106 million to finance further development of the company's lead candidate, an antibody treatment against two types of cancer. Sunstone Capital forebodes its exit from the company but takes its time.
The political ambitions of Danish life science are too low. Denmark’s lead position is at risk if politicians do not improve the conditions for the researchers and companies that are to create the drugs and hospital devices in future, says the Danish Chamber of Commerce's head of health policy.
Kasim Kutay, CEO of Novo Holdings, is ready to put large sums of money into diagnostics companies, an otherwise neglected industry among venture funds. Unstable success rates and difficult business models keep the investors away.
Danish Zealand Pharma has entered a collaboration agreement with Alexion that brings in the Danish biotech firm an upfront payment of DKK 165 million (USD 25 million). Depending on milestones, the deal can result in over DKK 4 billion (USD 610 million) for Zealand.
The Danish Association of the Pharmaceutical Industry (Lif), the government and the regional authorities have agreed on a new price ceiling that reduces the prices on hospital medicine by 12.5 percent. The reduction will happen gradually during a period of four years and according to Lif's CEO, it creates a much needed stability and predictability.
The founders of Danish medtech firm Particle3D have appointed former Bioporto manager Thea Wulff Olesen as CEO for their company that develops 3D-printed bone implants. Her long experience is to turn the startup into a public company.
After years of collaboration with Scandinavian public authorities, Danish company Dosesystem approaches the private market and signs a sales deal with a Belgium's largest pharmacy network.
There is still plenty of ambition and gumption left in Mads Krogsgaard Thomsen - the doyen of Novo Nordisk's executive management - and surrounded by a brand new team of VPs he is ready to spearhead the next major breakthroughs in the pharma group's research and development.
Swiss drug group Roche wants to increase awareness of the company as representative of the pharma industry and animate young biotech talents to choose a career in life science. One solution is a new partnership with Copenhagen Business School (CBS).
Hundreds of life science companies with over 42,500 employees have made the Oresund region an eldorado for venture funds looking for investment opportunities. "More attracts more," says one of the companies that have become keen on the region's life science hub.
Danish investment firm Novo Holdings, the owner of Novo Nordisk and Novozymes, earned 17 percentage point less return in 2018. However, the result still beats that of other large investment funds and the CEO is satisfied.
Three candidates are left in Danish Zealand Pharma's search for a new CEO. The company will soon initiate negotiations with them, says chairman.
After 18 years in Hillerød, Biogen has divested of its production facilities north of Copenhagen. The staff members keep their jobs under the new owner, Fujifilm, that will use the factory as external supplier.
Danish Avilex Pharma is about to initiate its first phase I trial with a candidate against ischemic stroke - an indication CEO Kristian Strømgaard calls the "graveyard of biotech."
About a year after its founding, Danish diagnostics company Fluoguide goes public with a product illuminating cancer cells. The company and its board are led by prominent names in the industry.
Danish hearing implant company Danaflex is no longer exclusive distributor of products from Australian hearing implant group Cochlear in Denmark. Instead, the company now has status as service provider, resulting in declined income and reduced profit. Nevertheless, the CEO is "more than satisfied" with the annual report.
Danish venture fund Sunstone Capital gets a new chairman as well as managing partner to ensure a smooth generational shift after the establishment of Sunstone's fourth biotech fund.
Novo Nordisk outpaces all other Danish life science companies, according to a new image report. The drug group only ranks low on one parameter.
Deborah Dunsire, CEO of Lundbeck, is prepared to give newly appointed chief business officer Keld Flintholm Jørgensen a cap of up to USD 5 billion for landing partnerships, licenses and acquisitions.
Biopharmaceutical giant Abbvie has also carried out huge firings in Sweden and Norway, after dismissing a third of the company's Danish staff in February. The company has also named new leaders of the Danish department and the company's new Scandinavian organization.
Biotech company Rhovac has hired Sweden's Anders Månsson to bolsters its operations and to conduct negotiations with potential buyers or partners for the company.
The listed Saniona spinout company Scandion Oncology has applied for a patent on a potential competitor and supplement to known antibiotics, but the company has no ambitions to bring the asset to the market itself.
